liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Economic Analysis of Ticagrelor Therapy From a US Perspective
Duke University, NC USA.
Duke University, NC USA.
Duke University, NC USA.
University of Alberta, Canada.
Show others and affiliations
2015 (English)In: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 65, no 5, 465-476 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND Based on results of the PLATO (Platelet Inhibition and Patient Outcomes) trial comparing ticagrelor with clopidogrel therapy, the U.S. Food and Drug Administration approved ticagrelor in 2011 for reducing thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) with the proviso that it be taken with low-dose aspirin. OBJECTIVES This study sought to assess the cost and cost effectiveness of ticagrelor therapy relative to clopidogrel in treating ACS patients from the perspective of the U.S. health care system. METHODS We estimated within-trial resource use and costs using U.S. low-dose aspirin patients in PLATO (n = 547). Quality-adjusted life expectancy was estimated using the total PLATO population (n = 18,624), combined with baseline risk and long-term survival data from an external ACS patient cohort. Study drugs were valued at current costs. Cost effectiveness was assessed, as was the sensitivity of results to sampling and methodological uncertainties. RESULTS One year of ticagrelor therapy, relative to that of generic clopidogrel, cost $29,665/quality-adjusted life-year gained, with 99% of bootstrap estimates falling under a $100,000 willingness-to-pay threshold. Results were robust to extensive sensitivity analyses, including variations in clopidogrel cost, exclusion of costs in extended years of life, and a recalibrated estimate of survival reflecting a lower underlying mortality risk in the United States. CONCLUSIONS For PLATO-eligible ACS patients, a U.S. perspective comparison of the current standard of dual antiplatelet therapy of aspirin with clopidogrel versus aspirin plus ticagrelor showed that the ticagrelor regimen increased life expectancy at an incremental cost well within accepted benchmarks of good value for money. (C) 2015 by the American College of Cardiology Foundation.

Place, publisher, year, edition, pages
2015. Vol. 65, no 5, 465-476 p.
Keyword [en]
acute coronary syndrome(s); antiplatelet therapy; clopidogrel; cost effectiveness; ticagrelor
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-114977DOI: 10.1016/j.jacc.2014.11.034ISI: 000348667000012PubMedID: 25660925OAI: diva2:794112

Funding Agencies|AstraZeneca; Eli Lilly Co.; Bristol-Myers Squibb/Pfizer; AGA Medical; Merck Co.; Boehringer-Ingelheim; GlaxoSmithKline; Pfizer; Gilead; Bristol-Myers Squibb; Accumetrics; Arisaph; CSL Behring; Essentialis; Janssen; Regeneron; Sanofi; Takeda; Baxter; Daiichi-Sankyo; Johnson Johnson; Medicines Company; Medtronic; WebMD; Portola Pharmaceuticals; Somahlution

Available from: 2015-03-10 Created: 2015-03-06 Last updated: 2016-04-14

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lundborg, ElisabetJanzon, MagnusLevin, Lars-Åke
By organisation
Division of Health Care AnalysisFaculty of Medicine and Health SciencesDivision of Cardiovascular MedicineDepartment of Cardiology in Linköping
In the same journal
Journal of the American College of Cardiology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 96 hits
ReferencesLink to record
Permanent link

Direct link